CRNX
Price
$45.28
Change
+$0.49 (+1.09%)
Updated
Feb 6 closing price
Capitalization
4.64B
18 days until earnings call
Intraday BUY SELL Signals
IDYA
Price
$32.17
Change
+$0.40 (+1.26%)
Updated
Feb 6 closing price
Capitalization
2.82B
51 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRNX vs IDYA

Header iconCRNX vs IDYA Comparison
Open Charts CRNX vs IDYABanner chart's image
Crinetics Pharmaceuticals
Price$45.28
Change+$0.49 (+1.09%)
Volume$2M
Capitalization4.64B
IDEAYA Biosciences
Price$32.17
Change+$0.40 (+1.26%)
Volume$985.32K
Capitalization2.82B
CRNX vs IDYA Comparison Chart in %
CRNX
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRNX vs. IDYA commentary
Feb 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 09, 2026
Stock price -- (CRNX: $45.28 vs. IDYA: $32.17)
Brand notoriety: CRNX and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 158% vs. IDYA: 106%
Market capitalization -- CRNX: $4.64B vs. IDYA: $2.82B
CRNX [@Biotechnology] is valued at $4.64B. IDYA’s [@Biotechnology] market capitalization is $2.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, CRNX is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 5 bearish.
  • IDYA’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than IDYA.

Price Growth

CRNX (@Biotechnology) experienced а -9.33% price change this week, while IDYA (@Biotechnology) price change was -0.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.30%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +31.79%.

Reported Earning Dates

CRNX is expected to report earnings on Feb 26, 2026.

IDYA is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (-2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($4.64B) has a higher market cap than IDYA($2.82B). CRNX YTD gains are higher at: -2.728 vs. IDYA (-6.942). IDYA has higher annual earnings (EBITDA): -204.84M vs. CRNX (-474.16M). CRNX has more cash in the bank: 1.09B vs. IDYA (787M). IDYA has less debt than CRNX: IDYA (27.2M) vs CRNX (49.1M). IDYA has higher revenues than CRNX: IDYA (215M) vs CRNX (1.54M).
CRNXIDYACRNX / IDYA
Capitalization4.64B2.82B165%
EBITDA-474.16M-204.84M231%
Gain YTD-2.728-6.94239%
P/E RatioN/AN/A-
Revenue1.54M215M1%
Total Cash1.09B787M139%
Total Debt49.1M27.2M181%
FUNDAMENTALS RATINGS
CRNX vs IDYA: Fundamental Ratings
CRNX
IDYA
OUTLOOK RATING
1..100
7166
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
5367
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
4852
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (50) in the Pharmaceuticals Major industry is in the same range as IDYA (50) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

CRNX's Profit vs Risk Rating (53) in the Pharmaceuticals Major industry is in the same range as IDYA (67) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as CRNX (97) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as IDYA (52) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXIDYA
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 25 days ago
75%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
76%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ROFCX13.590.48
+3.66%
Royce Small-Cap Opportunity Consult
CNWCX94.542.06
+2.23%
American Funds New World 529C
IYCEX16.910.36
+2.18%
Nomura Core Equity Fund Class R
BTIRX166.113.21
+1.97%
DWS Equity 500 Index R6
JIAIX9.830.08
+0.82%
JHancock Multi-Asset High Income I

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.09%
XNCR - CRNX
60%
Loosely correlated
+7.30%
NUVL - CRNX
55%
Loosely correlated
+2.67%
DYN - CRNX
55%
Loosely correlated
+1.51%
IDYA - CRNX
55%
Loosely correlated
+1.26%
RLAY - CRNX
53%
Loosely correlated
+9.45%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been closely correlated with IMNM. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+1.26%
IMNM - IDYA
68%
Closely correlated
+3.67%
NRIX - IDYA
67%
Closely correlated
+5.64%
IMVT - IDYA
66%
Loosely correlated
+12.43%
NUVL - IDYA
65%
Loosely correlated
+2.67%
SYRE - IDYA
65%
Loosely correlated
+6.62%
More